These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36537980)

  • 1. Muscle Channelopathies.
    Trivedi JR
    Continuum (Minneap Minn); 2022 Dec; 28(6):1778-1799. PubMed ID: 36537980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle channelopathies.
    Statland J; Phillips L; Trivedi JR
    Neurol Clin; 2014 Aug; 32(3):801-15, x. PubMed ID: 25037091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal Muscle Channelopathies.
    Vivekanandam V; Munot P; Hanna MG; Matthews E
    Neurol Clin; 2020 Aug; 38(3):481-491. PubMed ID: 32703462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostics in skeletal muscle channelopathies.
    Vicino A; Brugnoni R; Maggi L
    Expert Rev Mol Diagn; 2023; 23(12):1175-1193. PubMed ID: 38009256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.
    Platt D; Griggs R
    Curr Opin Neurol; 2009 Oct; 22(5):524-31. PubMed ID: 19571750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle channelopathies.
    Saperstein DS
    Semin Neurol; 2008 Apr; 28(2):260-9. PubMed ID: 18351527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What the internist should know about hereditary muscle channelopathies.
    Bissay V; Van Malderen SCH
    Acta Clin Belg; 2018 Feb; 73(1):1-6. PubMed ID: 29088983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence study of genetically defined skeletal muscle channelopathies in England.
    Horga A; Raja Rayan DL; Matthews E; Sud R; Fialho D; Durran SC; Burge JA; Portaro S; Davis MB; Haworth A; Hanna MG
    Neurology; 2013 Apr; 80(16):1472-5. PubMed ID: 23516313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle channelopathies: the nondystrophic myotonias and periodic paralyses.
    Statland JM; Barohn RJ
    Continuum (Minneap Minn); 2013 Dec; 19(6 Muscle Disease):1598-614. PubMed ID: 24305449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nondystrophic myotonias.
    Heatwole CR; Moxley RT
    Neurotherapeutics; 2007 Apr; 4(2):238-51. PubMed ID: 17395134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric neuromuscular channelopathies.
    Vivekanandam V; Munot P; Jayaseelan DL
    Handb Clin Neurol; 2024; 203():111-122. PubMed ID: 39174243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnosis and treatment of myotonic disorders.
    Heatwole CR; Statland JM; Logigian EL
    Muscle Nerve; 2013 May; 47(5):632-48. PubMed ID: 23536309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and genetic spectrum of a Chinese cohort with SCN4A gene mutations.
    Sun J; Luo S; Suetterlin KJ; Song J; Huang J; Zhu W; Xi J; Zhou L; Lu J; Lu J; Zhao C; Hanna MG; Männikkö R; Matthews E; Qiao K
    Neuromuscul Disord; 2021 Sep; 31(9):829-838. PubMed ID: 33965302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle channelopathies and related diseases.
    Fontaine B
    Handb Clin Neurol; 2013; 113():1433-6. PubMed ID: 23622365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal muscle channelopathies: a guide to diagnosis and management.
    Matthews E; Holmes S; Fialho D
    Pract Neurol; 2021 Jun; 21(3):196-204. PubMed ID: 33563766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation spectrum and health status in skeletal muscle channelopathies in Japan.
    Sasaki R; Nakaza M; Furuta M; Fujino H; Kubota T; Takahashi MP
    Neuromuscul Disord; 2020 Jul; 30(7):546-553. PubMed ID: 32660787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel mutations in human and mouse SCN4A implicate AMPK in myotonia and periodic paralysis.
    Corrochano S; Männikkö R; Joyce PI; McGoldrick P; Wettstein J; Lassi G; Raja Rayan DL; Blanco G; Quinn C; Liavas A; Lionikas A; Amior N; Dick J; Healy EG; Stewart M; Carter S; Hutchinson M; Bentley L; Fratta P; Cortese A; Cox R; Brown SD; Tucci V; Wackerhage H; Amato AA; Greensmith L; Koltzenburg M; Hanna MG; Acevedo-Arozena A
    Brain; 2014 Dec; 137(Pt 12):3171-85. PubMed ID: 25348630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug repurposing in skeletal muscle ion channelopathies.
    Altamura C; Saltarella I; Campanale C; Laghetti P; Desaphy JF
    Curr Opin Pharmacol; 2023 Feb; 68():102329. PubMed ID: 36512979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands.
    Stunnenberg BC; Raaphorst J; Deenen JCW; Links TP; Wilde AA; Verbove DJ; Kamsteeg EJ; van den Wijngaard A; Faber CG; van der Wilt GJ; van Engelen BGM; Drost G; Ginjaar HB
    Neuromuscul Disord; 2018 May; 28(5):402-407. PubMed ID: 29606556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle channelopathies.
    Vivekanandam V; Jayaseelan D; Hanna MG
    Handb Clin Neurol; 2023; 195():521-532. PubMed ID: 37562884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.